Zai Lab Limited (ZLAB) Reports Q2 Loss of $0.82, Beats on Revenue

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Zai Lab Limited (ZLAB) Reports Q2 Loss of $0.82, Beats on Revenue

Zai Lab Announces Second Quarter 2024 Financial Results and Recent Corporate Updates

August 6, 2024 4:05 PM EDT

Net product revenue of $100.1 million for the second quarter of 2024, representing 45% y-o-y growth; 47% y-o-y growth at constant exchange rate (CER)

VYVGART® (efgartigimod alfa injection) sales of $23.2 million for the second quarter of 2024; raising full-year VYVGART revenue guidance to exceed $80.0 million

Expansion of Zai Labs global oncology pipeline with a next generation ROR1 antibody-drug conjugate (ADC) program

Three product approvals in China including XACDURO® for HABP/VABP, efgartigimod SC for gMG, and AUGTYRO for ROS1+ NSCLC; expect at least four regulatory submissions to the NMPA within next 12 months including KarXT for... More